NEC, together with the Japan Cancer Research Institute (JFCR) and Taiho Pharmaceutical, publicized a partnership to create and produce neoantigen-based cancer vaccines that will be shared. The focus of these vaccines is on the tumour-specific neoantigens that are common in several patients aiming to give "off-the-shelf" immunotherapy options instead of completely personalized ones. This action indicates the increasing trend in cancer-vaccine research and development and could lead to partnerships and licensing opportunities worldwide in the future.
Source Reference:
NEC / JFCR / Taiho press release — Nov 28, 2025 NEC Global
